Close Menu

NEW YORK – The US Food and Drug Administration on Tuesday granted accelerated approval to Genentech and Blueprint Medicine's RET inhibitor pralsetinib (Gavreto) for patients with advanced or metastatic RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer.

This is the second precision medicine option for patients with these types of cancers, following the FDA's approval of selpercatinib (Eli Lilly's Retevmo) in May.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.